false 0001430306 0001430306 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED
STATES SECURITIES
AND EXCHANGE COMMISSION Washington,
D.C. 20549 FORM 8-K CURRENT
REPORT Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date
of report (date of earliest event reported): July 20, 2026 TONIX
PHARMACEUTICALS HOLDING CORP. (Exact
name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State
                                            or Other Jurisdiction of
    Incorporation) (Commission File
    Number) (IRS
                                            Employer Identification
    No.) 200
Connell Drive , Suite 3100 , Berkeley Heights , New Jersey 07922 (Address
of principal executive offices) (Zip Code) Registrant’s
telephone number, including area code: (862) 799-8599 Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): ☐ Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities
registered pursuant to Section 12(b) of the Act: Title
    of each class Trading
    Symbol(s) Name
    of each exchange on which registered Common
    Stock TNXP The NASDAQ Global
    Select Market Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging
growth company ☐ If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. On
July 20, 2026, Dr. Gregory M. Sullivan informed Tonix Pharmaceuticals Holding Corp. (the “Company”) that he will retire from
his role as Chief Medical Officer of the Company, effective August 20, 2026. SIGNATURE Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized. TONIX
    PHARMACEUTICALS HOLDING CORP. Date:
    July 21, 2026 By: /s/
    Bradley Saenger Bradley
    Saenger Chief
    Financial Officer

Dr. Gregory M. Sullivan, Chief Medical Officer of Tonix Pharmaceuticals, announced his retirement effective August 20, 2026. This executive departure may impact the company's pharmaceutical development strategy and investor confidence during a critical period.

On July 20, 2026, Dr. Gregory M. Sullivan announced his retirement from his position as Chief Medical Officer of Tonix Pharmaceuticals Holding Corp., with his retirement effective on August 20, 2026. This change in the management team may impact the company's strategic direction, particularly in the development of its pharmaceutical products. The company will need to consider a replacement for Dr. Sullivan and the potential implications this may have on ongoing projects and investor confidence.

Tonix Pharmaceuticals Holding Corp.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means